Kristi Rosa

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) whose disease progressed after chemotherapy.

Durvalumab improved progression-free survival in unresectable NSCLC patients without progression post-chemoradiotherapy, reducing disease progression risk by 25% compared to placebo.

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma.

Zongertinib achieved a 71% objective response rate and 93% disease control rate in patients with HER2-mutant NSCLC at a dose of 120 mg.

Lenvatinib showed a median PFS of 5.4 months in advanced HCC patients following treatment with atezolizumab/bevacizumab, meeting the primary endpoint.

The combination treatment of elacestrant and abemaciclib provided clinical benefit with acceptable safety in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

Neoadjuvant camrelizumab paired with chemotherapy could represent a new option in early or locally advanced triple-negative breast cancer.

Neoadjuvant patritumab deruxtecan demonstrated comparable responses with lower high-grade adverse effects in patients with high-risk, HR–positive, HER2-negative breast cancer.

Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

Based on findings from a phase 2 expansion cohort, the FDA granted breakthrough therapy designation to sacituzumab tirumotecan for use in select patients with EGFR+ non–small cell lung cancer.

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.

Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC.

Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.

The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma.

The duo of TAR-200 and cetrelimab was safe and efficacious in the neoadjuvant setting for certain patients with muscle-invasive bladder cancer.

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced cervical cancer.

The addition of BMS-986012 to frontline nivolumab and chemotherapy led to promising outcomes in patients with extensive-stage small cell lung cancer.

DESTINY-Breast12 results showed that T-DXd led to overall and intracranial activity in patients with HER2-positive metastatic breast cancer.

The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.

Breakthrough therapy designation has been granted by the FDA to GSK5764227 for potential use in some patients with extensive-stage SCLC.

A CRL has been issued by the FDA to the biologics license application seeking approval of linvoseltamab to treat some patients with multiple myeloma.

Bintrafusp alfa induced responses in recurrent/metastatic cervical cancer, supporting the need for further research into TGF-β-targeted therapies.

Treatment with pembrolizumab and chemotherapy for head and neck squamous cell carcinoma provided responses with a manageable safety profile.

Atezolizumab was safe and effective when administered before and following chemoradiation in unresectable stage III non–small cell lung cancer.

Treatment with paxalisib in patients with newly diagnosed unmethylated glioblastoma was well tolerated with no new safety signals.

Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT.